NCT02936102 A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. Status TERMINATED Phase PHASE1
NCT02900157 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02880371 A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Status TERMINATED Phase PHASE1/PHASE2
NCT02875548 A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study Status COMPLETED Phase PHASE1/PHASE2
NCT02844881 Study of Apatinib and MASCT in Patients With Advanced Solid Tumors Status UNKNOWN Phase PHASE1/PHASE2
NCT02834247 A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors Status TERMINATED Phase PHASE1
NCT02829723 A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors Status TERMINATED Phase PHASE1/PHASE2
NCT02799095 A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT02797977 A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects Status COMPLETED Phase PHASE1/PHASE2
NCT02743637 A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors Status COMPLETED Phase PHASE1
NCT02734433 Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02729298 First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02721589 A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects Status COMPLETED Phase PHASE1
NCT02693535 TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Status RECRUITING Phase PHASE2
NCT02690350 An Open Study Assessing the Safety and Tolerability of U3-1784 Status TERMINATED Phase PHASE1
NCT02671435 A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT02644369 Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02622932 Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients Status COMPLETED Phase PHASE1
NCT02614456 Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors Status COMPLETED Phase PHASE1